Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oral drug delivery
Biotech
Viking hits stormy seas as phase 2 oral obesity data sink stock
Viking saw weight loss of up to 12.2%. But with 38% of patients discontinuing treatment at the most effective dose, investors sent the stock down 37%.
Nick Paul Taylor
Aug 19, 2025 9:44am
MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b
Jun 24, 2025 10:06am
AstraZeneca pens $5.3B pact with CSPC to develop oral drugs
Jun 13, 2025 5:56am
Merck links up with Cyprumed in $493M oral peptide deal
Apr 15, 2025 1:11pm
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
Nov 19, 2024 11:44am
Lilly's lipoprotein-blocking heart drug posts midstage trial win
Nov 19, 2024 9:55am
